Novo Nordisk's Post-Patent Strategy

Novo Nordisk currently sits atop a roughly $20 billion Ozempic/Wegovy franchise that faces patent expiration in 2031 — roughly seven years to establish a successor. We revisit them today, since per newly published Lancet data, Novo’s lead replacement candidate, amycretin, has reported its Phase 1 results. The primary published metrics are weight-loss percentages versus placebo over a 36-week period; readers interested in head-to-head comparisons against currently approved therapies should consult the trial publications directly rather than rely on cross-trial inferences. Amycretin is a peptide combining the semaglutide GLP-1 mechanism with amylin receptor agonism, designed to engage two satiety pathways simultaneously rather than one. Elaine Chen at STAT covered the trial with a focus on the dose-response data; the full text is behind a paywall.

What is interesting from a development-design standpoint is that the dose-response curves in Figure 3 show relatively similar trajectories across the overlapping time periods, with gastrointestinal side effects scaling with dose. Drug development usually expects clear separation between dose groups; relatively flat curves could indicate that the molecule reaches maximum effect at lower doses than the maximum tolerated dose. If that pattern holds in Phase 3, the trial design question becomes “lowest effective” rather than “maximum tolerated,” which is a more conservative regulatory path.

From a financial perspective, Novo Nordisk’s pipeline is very interesting: Amycretin’s injectable version is currently in Phase 2, suggesting Phase 3 trials around 2026-2027, with potential approval by 2031; basically right as the Ozempic patents expire. But Novo isn’t betting everything on amycretin. They’re running what appears to be a diversified pipeline strategy with multiple shots on goal: NNC-0519 (another next-gen GLP-1), NNC-0662 (details kept confidential), and cagrilintide combinations. This makes sense: you want multiple candidates because the failure rate in drug development makes even the most promising compounds statistically likely to fail. Eli Lilly’s tirzepatide (Mounjaro/Zepbound) works through a different mechanism—GLP-1 plus GIP receptor activation—and appears to be gaining market share. Lilly’s orforglipron, an oral GLP-1 that hit 14.7% weight loss in Phase 2, represents another competitive threat. Judging by LLY’s price development, investors currently seem to think that Lilly is doing a better job at architecting a portfolio than Novo (or at least providing more disclosure about their pipeline). Yet, the overall competitive landscape might actually benefit both companies. The “war” between Novo and Lilly is expanding the overall market for obesity treatments, potentially growing the pie faster than either company is losing share. Also, to analyze the financial impact of the expiring Ozempic patents, we have to look further than just Novo’s research pipeline. Manufacturing these GLP-1 compounds and their delivery devices is “pretty tough.” Complex peptides requiring specialized manufacturing capabilities, plus the injection devices themselves are patent-protected. This creates what we would call a capacity constraint moat in corporate strategy. Novo’s manufacturing capabilities/partnerships and injectable device patents are a key competitive advantage. Even when semaglutide goes generic in 2031, the entire generic pharmaceutical industry would essentially need to coordinate to build sufficient manufacturing capacity to meaningfully dent Novo’s market share. Meanwhile, Novo could potentially defend by lowering prices while maintaining manufacturing advantages in a monopoly-to-oligopoly transition.

Publicly available sell-side and independent models on Novo show a wide range of fair-value estimates because the binary nature of pipeline outcomes makes valuation highly path-dependent. The structural point worth making, independent of any specific price target, is that manufacturing capabilities and a continuous innovation pipeline can in principle defend a quasi-monopolistic position longer than a small-molecule patent cliff alone would suggest. Whether that defense actually holds in Novo’s case is contingent on Phase 3 execution and on what the competitive landscape looks like in 2031.